- Kura Oncology (KURA, Financial) to report first quarter 2025 financial results on May 1, 2025.
- Earnings call scheduled at 4:30 p.m. ET / 1:30 p.m. PT with webcast and conference call access.
- Active development in cancer treatment through precision medicines with recent NDA submission.
Kura Oncology (KURA), a clinical-stage biopharmaceutical company specializing in precision cancer medicines, has announced the release of its first quarter 2025 financial results after the U.S. market closes on Thursday, May 1, 2025.
The company's management team will conduct a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial performance and provide a corporate update. Interested investors can participate in the live call by dialing (800) 245-3047 for domestic callers or (203) 518-9765 for international callers and using the conference ID: KURAQ1. The event can also be accessed via a live webcast available through the investor relations section of Kura's website, with a replay available post-event.
Kura Oncology is committed to advancing precision medicines for cancer treatment, with a notable pipeline that includes small molecule drug candidates targeting cancer signaling pathways. A key development includes their investigational therapy, ziftomenib, which has received Breakthrough Therapy Designation from the U.S. FDA for treating relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). In a strategic collaboration with Kyowa Kirin, Kura has recently submitted a New Drug Application (NDA) for ziftomenib aimed at adult patients with relapsed/refractory NPM1-mutant AML, following the completion of a Phase 2 trial.
Beyond ziftomenib, Kura is also advancing other promising treatments such as KO-2806, a next-generation farnesyl transferase inhibitor currently in Phase 1 trials, and Tipifarnib, which is being tested in combination therapies for head and neck squamous cell carcinoma.
For more information, please visit Kura Oncology's investor relations website.
